Related Experiment Video
Updated: Mar 5, 2026
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
[The effect of methylphenidate on appetite and weight]
R Bou Khalil1, N Fares2, Y Saliba2
1Département de psychiatrie, faculté de médecine, université Saint-Joseph, campus des sciences médicales de l'USJ, rue de Damas, Achrafieh, BP 17-5208, Mar-Mikhaël, Beyrouth 1104 2020, Liban; Service de psychiatrie, Hôtel-Dieu-de-France, Beyrouth, Liban.
Objectives:
To better delineate in the medical literature the effect of methylphenidate on weight and appetite.
Methods:
A search on PubMed was carried out for articles published with no restrictions on language or year of publication using the terms: "methylphenidate"; "weight"; "appetite".
Results:
Methylphenidate increases dopamine and noradrenaline in synapses because of its blockage of the transporters of these monoamines in the frontal cortex and insular lobe. The intracerebral activity of methylphenidate is incriminated in the dysregulation of appetite due to its probable effect stimulating the disgust sensation generated after the activation of the insular lobe by the drug. The anorexigenic effect of methylphenidate has been demonstrated in preclinical studies although the dosage and the administration routes differ in animals from those used for human beings. In clinical studies, methylphenidate decreases the weight of children and adolescents during the first 3 to 6 months after its initiation due to the appetite reduction effect that it generates with a tendency of weight curves to rejoin the curves of subjects who did not receive the treatment a few years after its initiation.
Conclusion:
The anorexigenic effect of methylphenidate does not persist over the long-term in children and adolescents who receive it.
Related Concept Videos
01:30Regulation of Food Intake
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
01:23Antidepressant Drugs: MAOIs and Other Agents
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...